股本结构
单位：万股
| 公告日期 | 2026-08-06 | 2026-08-06 | 2026-04-23 | 2026-05-07 | 2026-02-26 | 2026-02-26 |
|---|---|---|---|---|---|---|
| 证券总股本 | 14719.89 | 13982.43 | 13966.37 | 13965.28 | 12059.52 | 12049.94 |
| 普通股本 | 14719.89 | 13982.43 | 13966.37 | 13965.28 | 12059.52 | 12049.94 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-07-31 | 2026-06-30 | 2026-04-14 | 2026-03-31 | 2026-01-30 | 2025-12-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-08-06 | 14719.89 | 未披露 | 定期报告 | 2026-07-31 |
| 2026-08-06 | 13982.43 | 未披露 |
更多>>
From March 31,2026 to June 30,2026
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
|
2026-06-30 |
| 2026-04-23 | 13966.37 | 未披露 | 定期报告 | 2026-04-14 |
| 2026-05-07 | 13965.28 | 未披露 |
更多>>
From December 31,2025 to March 31,2026
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
Issuance of common stock under at-the-market sales agreement, net of offering costs of $1,884
|
2026-03-31 |
| 2026-02-26 | 12059.52 | 未披露 | 定期报告 | 2026-01-30 |
| 2026-02-26 | 12049.94 | 未披露 |
更多>>
From December 31, 2024 to December 31, 2025
Issuance of common stock in connection with vesting of restricted stock units
Exercise of common stock purchase warrants
|
2025-12-31 |
| 2025-11-06 | 10834.52 | 未披露 | 定期报告 | 2025-10-31 |
| 2025-11-06 | 10834.26 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Issuance of common stock in connection with vesting of restricted stock units
|
2025-09-30 |
| 2025-08-07 | 10833.22 | 未披露 | 定期报告 | 2025-07-31 |
| 2025-08-07 | 10832.88 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of common stock in connection with vesting of restricted stock units
|
2025-06-30 |
| 2025-04-24 | 10828.12 | 未披露 | 定期报告 | 2025-04-04 |
| 2025-05-08 | 10826.55 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of common stock in connection with vesting of restricted stock units
|
2025-03-31 |
| 2025-04-24 | 10814.83 | 未披露 | 定期报告 | 2025-02-10 |
| 2025-02-27 | 10791.88 | 未披露 | 定期报告 | 2025-01-31 |
| 2025-02-27 | 10785.01 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
Issuance of common stock under securities purchase agreement, net of offering costs of $5,087
|
2024-12-31 |
| 2024-12-19 | 10701.87 | 未披露 | 定期报告 | 2024-12-16 |
| 2024-11-18 | 10698.65 | 未披露 |
更多>>
Aclaris Therapeutics Inc.issues 35,555,555 shares of the Company’s Common Stock.
|
2024-11-19 |
| 2024-11-06 | 7143.09 | 未披露 | 定期报告 | 2024-10-31 |
| 2024-11-06 | 7141.75 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
|
2024-09-30 |
| 2024-08-07 | 7134.46 | 未披露 | 定期报告 | 2024-07-31 |
| 2024-08-07 | 7133.28 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of common stock in connection with vesting of restricted stock units
|
2024-06-30 |
| 2024-04-25 | 7126.48 | 未披露 | 定期报告 | 2024-04-16 |
| 2024-05-07 | 7124.80 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Issuance of common stock in connection with vesting of restricted stock units
|
2024-03-31 |
| 2024-02-27 | 7092.50 | 未披露 | 定期报告 | 2024-01-31 |
| 2024-02-27 | 7089.49 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
Issuance of common stock under at-the-market sales agreement, net of offering costs of $826
|
2023-12-31 |
| 2023-11-06 | 7083.62 | 未披露 | 定期报告 | 2023-10-31 |
| 2023-11-06 | 7081.90 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
|
2023-09-30 |
| 2023-08-07 | 7079.46 | 未披露 | 定期报告 | 2023-07-31 |
| 2023-08-07 | 7076.97 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
Issuance of common stock under at-the-market sales agreement, net of offering costs of $826
|
2023-06-30 |
| 2023-04-20 | 7067.94 | 未披露 | 定期报告 | 2023-04-04 |
| 2023-05-08 | 6720.60 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of common stock in connection with vesting of restricted stock units
|
2023-03-31 |
| 2023-02-23 | 6669.30 | 未披露 | 定期报告 | 2023-01-31 |
| 2023-02-23 | 6668.86 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
Issuance of common stock under at-the-market sales agreement, net of offering costs of $2,341,000
|
2022-12-31 |
| 2022-11-08 | 6668.32 | 未披露 | 定期报告 | 2022-10-31 |
| 2022-11-08 | 6667.96 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of common stock in connection with vesting of restricted stock units
|
2022-09-30 |
| 2022-08-03 | 6667.18 | 未披露 | 定期报告 | 2022-07-29 |
| 2022-08-03 | 6666.76 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
Issuance of common stock under at-the-market sales agreement, net of offering costs of $2,341
|
2022-06-30 |
| 2022-05-10 | 6658.19 | 未披露 | 定期报告 | 2022-04-29 |
| 2022-04-14 | 6611.37 | 未披露 |
更多>>
1.On April 13, 2022, Aclaris Therapeutics, Inc. (the “Company”) sold 4,838,709 shares of its common stock at a weighted average price per share of $15.50, for aggregate gross proceeds of $75.0 million. The shares were sold pursuant to a sales agreement with SVB Securities LLC and Cantor Fitzgerald & Co. dated May 20, 2021.
|
2022-04-13 |
| 2022-04-21 | 6174.17 | 未披露 | 定期报告 | 2022-04-12 |
| 2022-05-10 | 6173.75 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
|
2022-03-31 |
| 2022-02-24 | 6127.50 | 未披露 | 定期报告 | 2022-01-31 |
| 2022-02-24 | 6122.84 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock in connection with exercise of stock options and warrants and vesting of restricted stock units
Issuance of common stock in connection with public offering, net of offering costs of $15,910
|
2021-12-31 |
| 2021-11-02 | 6122.73 | 未披露 | 定期报告 | 2021-10-29 |
| 2021-11-02 | 6122.68 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock in connection with vesting of restricted stock units
|
2021-09-30 |
| 2021-08-05 | 6121.57 | 未披露 | 定期报告 | 2021-07-30 |
| 2021-08-05 | 6120.50 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of common stock in connection with exercise of stock options and warrants and vesting of restricted stock units
Issuance of common stock in connection with public offering, net of offering costs of $8,899
|
2021-06-30 |
| 2021-06-14 | 5912.40 | 未披露 |
更多>>
1.Common Stock offered by Aclaris 7,042,254 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 52,081,729 shares of common stock outstanding as of March 31, 2021.
|
2021-06-14 |
| 2021-05-07 | 5210.74 | 未披露 | 定期报告 | 2021-04-30 |
| 2021-04-22 | 5208.49 | 未披露 | 定期报告 | 2021-04-05 |
| 2021-05-07 | 5208.17 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Issuance of common stock in connection with exercise of stock options and warrants and vesting of restricted stock units
Issuance of common stock in connection with public offering, net of offering costs of $7,011
|
2021-03-31 |
| 2021-02-25 | 5180.43 | 未披露 | 定期报告 | 2021-01-31 |
| 2021-01-22 | 4840.01 | 未披露 |
更多>>
1.Common Stock offered by Aclaris 5,483,714 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 42,916,387 shares of common stock outstanding as of September 30, 2020.
|
2021-01-22 |
| 2021-02-25 | 4510.93 | 未披露 |
更多>>
From December 31,2019 to December 31,2020
Vesting of restricted stock units
Issuance of common stock in connection with an equity purchase agreement, net of offering costs of $168,000
|
2020-12-31 |
| 2020-11-04 | 4291.93 | 未披露 | 定期报告 | 2020-10-31 |
| 2020-11-04 | 4291.64 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Vesting of restricted stock units
Issuance of common stock in connection with equity purchase agreement
|
2020-09-30 |
| 2020-08-07 | 4272.28 | 未披露 | 定期报告 | 2020-08-06 |
| 2020-08-07 | 4269.11 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Vesting of restricted stock units
|
2020-06-30 |
| 2020-05-07 | 4186.63 | 未披露 | 定期报告 | 2020-05-06 |
| 2020-05-07 | 4183.22 | 未披露 |
更多>>
From December 31, 2019 to March 31, 2020
Vesting of RSUs
|
2020-03-31 |
| 2020-02-25 | 4152.88 | 未披露 | 定期报告 | 2020-02-24 |
| 2020-02-25 | 4148.56 | 未披露 |
更多>>
From December 31, 2018 to December 31, 2019
Exercise of stock options and vesting of RSUs
|
2019-12-31 |
| 2019-11-07 | 4138.84 | 未披露 | 定期报告 | 2019-11-07 |
| 2019-11-07 | 4138.08 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Exercise of stock options and vesting of RSUs
|
2019-09-30 |
| 2019-08-08 | 4136.82 | 未披露 | 定期报告 | 2019-08-05 |
| 2019-08-08 | 4127.86 | 未披露 |
更多>>
from March 31, 2019 to June 30, 2019
Exercise of stock options and vesting of RSUs
|
2019-06-30 |
| 2019-05-08 | 4127.23 | 未披露 | 定期报告 | 2019-05-07 |
| 2019-05-08 | 4126.96 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Vesting of RSUs
|
2019-03-31 |
| 2019-03-18 | 4126.96 | 未披露 | 定期报告 | 2019-03-15 |
| 2019-04-25 | 4125.64 | 未披露 | 定期报告 | 2019-02-01 |
| 2019-03-18 | 4121.07 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Issuance of common stock in connection with public offering, net of offering costs of $6,669
Issuance of common stock in connection with the Confluence development milestone
Exercise of stock options and vesting of RSUs
|
2018-12-31 |
| 2018-11-06 | 4093.62 | 未披露 | 定期报告 | 2018-11-05 |
| 2018-11-06 | 3099.11 | 未披露 |
更多>>
From December 31, 2017 to September 30, 2018
Exercise of stock options and vesting of RSUs
|
2018-09-30 |
| 2018-08-03 | 3098.07 | 未披露 | 定期报告 | 2018-08-02 |
| 2018-08-03 | 3096.53 | 未披露 |
更多>>
from December 31, 2017 to June 30, 2018
Exercise of stock options and vesting of RSUs
|
2018-06-30 |
| 2018-04-26 | 3090.60 | 未披露 | 定期报告 | 2018-04-16 |
| 2018-05-08 | 3090.56 | 未披露 |
更多>>
from December 31, 2017 to March 31, 2018
Exercise of stock options and vesting of RSUs
|
2018-03-31 |
| 2018-03-12 | 3090.15 | 未披露 | 定期报告 | 2018-03-09 |
| 2018-04-26 | 3088.01 | 未披露 | 定期报告 | 2018-02-01 |
| 2018-03-12 | 3085.65 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Issuance of common stock under the at-the-market sales agreement, net of offering costs of $691
Issuance of common stock in connection with public offering, net of offering costs of $5,352
Issuance of common stock in connection with the acquisition of Confluence
Exercise of stock options and vesting of RSUs
|
2017-12-31 |
| 2017-11-07 | 3083.47 | 未披露 |
更多>>
From December 31, 2016 to September 30, 2017
Issuance of common stock under the at-the-market sales agreement, net of offering costs of $691
Issuance of common stock in connection with public offering, net of underwriting discounts and commissions and offering costs of $5,352
Issuance of common stock in connection with the acquisition of Confluence
Exercise of stock options and vesting of restricted stock units
|
2017-09-30 |
| 2017-08-08 | 2673.65 | 未披露 |
更多>>
From December 31, 2016 to June 30, 2017
Issuance of common stock under the at-the-market sales agreement, net of offering costs of $691
Exercise of stock options and vesting of restricted stock units
|
2017-06-30 |
| 2017-05-09 | 2673.35 | 未披露 | 定期报告 | 2017-05-08 |
| 2017-04-21 | 2609.85 | 未披露 | 定期报告 | 2017-04-17 |
| 2017-05-09 | 2609.71 | 未披露 |
更多>>
from December 31, 2016 to March 31, 2017
Exercise of stock options and vesting of restricted stock units
|
2017-03-31 |
| 2017-03-15 | 2608.89 | 未披露 | 定期报告 | 2017-03-14 |
| 2017-04-21 | 2608.13 | 未披露 | 定期报告 | 2017-03-03 |
| 2017-03-15 | 2605.92 | 未披露 |
更多>>
From December 31, 2015 to December 31, 2016
Issuance of common stock in connection with Vixen acquisition
Issuance of common stock in connection with private placement, net of offering costs of $1,453
Issuance of common stock in connection with follow-on public offering, net of offering costs of $6,492
Exercise of stock options and vesting of RSUs
|
2016-12-31 |
| 2016-11-03 | 2143.29 | 未披露 | 定期报告 | 2016-11-02 |
| 2016-11-03 | 2142.40 | 未披露 |
更多>>
From December 31, 2015 to September 30, 2016
Issuance of common stock in connection with Vixen acquisition
Issuance of common stock in connection with private placement, net of offering costs of $1,453
Exercise of stock options
|
2016-09-30 |
| 2016-08-11 | 2141.54 | 未披露 | 定期报告 | 2016-08-10 |
| 2016-08-11 | 2140.30 | 未披露 |
更多>>
from December 31, 2015 to June 30, 2016
Issuance of common stock in connection with Vixen acquisition
Issuance of common stock in connection with private placement, net of offering costs of $1,453,000
Exercise of stock options
|
2016-06-30 |
| 2016-06-17 | 2140.30 | 未披露 | 定期报告 | 2016-06-10 |
| 2016-05-11 | 2031.69 | 未披露 |
更多>>
from December 31, 2015 to March 31, 2016
Issuance of common stock in connection with Vixen acquisition
|
2016-03-31 |
| 2016-03-23 | 2015.75 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Issuance of Series C convertible preferred stock, net of issuance costs of $136
Issuance of common stock in connection with IPO, net of offering costs of $2,272
Issuance of common stock upon conversion of convertible preferred stock
On September 24, 2015, the Company effected a 1-for-3.45 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company’s then-outstanding convertible preferred stock.
|
2015-12-31 |
| 2015-11-18 | 2015.75 | 未披露 | 定期报告 | 2015-11-17 |
| 2015-10-08 | 1940.75 | 未披露 |
更多>>
a 1-for-3.45 reverse stock split of our common stock effected on September 24, 2015
|
2015-10-07 |
| 2015-11-18 | 273.04 | 4028.60 |
更多>>
from January 1, 2015 to September 30, 2015
Issuance of Series C convertible preferred stock, net of issuance costs of $136
On September 24, 2015, the Company effected a one-for-3.45 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company's convertible preferred stock
|
2015-09-30 |
| 2015-09-25 | 273.04 | 2734.11 |
更多>>
On September 24, 2015, the Company effected a one-for-3.45 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company's convertible preferred stock
|
2015-09-25 |
| 2015-08-17 | 942.00 | 2734.11 |
更多>>
from December 31, 2014 to June 30, 2015
Accretion of redeemable convertible preferred stock to redemption value
|
2015-06-30 |
From March 31,2026 to June 30,2026
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
From December 31,2025 to March 31,2026
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
Issuance of common stock under at-the-market sales agreement, net of offering costs of $1,884
From December 31, 2024 to December 31, 2025
Issuance of common stock in connection with vesting of restricted stock units
Exercise of common stock purchase warrants
From June 30, 2025 to September 30, 2025
Issuance of common stock in connection with vesting of restricted stock units
From March 31, 2025 to June 30, 2025
Issuance of common stock in connection with vesting of restricted stock units
From December 31, 2024 to March 31, 2025
Issuance of common stock in connection with vesting of restricted stock units
From December 31, 2023 to December 31, 2024
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
Issuance of common stock under securities purchase agreement, net of offering costs of $5,087
Aclaris Therapeutics Inc.issues 35,555,555 shares of the Company’s Common Stock.
From June 30, 2024 to September 30, 2024
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
From March 31, 2024 to June 30, 2024
Issuance of common stock in connection with vesting of restricted stock units
From December 31, 2023 to March 31, 2024
Issuance of common stock in connection with vesting of restricted stock units
From December 31, 2022 to December 31, 2023
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
Issuance of common stock under at-the-market sales agreement, net of offering costs of $826
From June 30, 2023 to September 30, 2023
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
From March 31, 2023 to June 30, 2023
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
Issuance of common stock under at-the-market sales agreement, net of offering costs of $826
From December 31, 2022 to March 31, 2023
Issuance of common stock in connection with vesting of restricted stock units
From December 31, 2021 to December 31, 2022
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
Issuance of common stock under at-the-market sales agreement, net of offering costs of $2,341,000
From June 30, 2022 to September 30, 2022
Issuance of common stock in connection with vesting of restricted stock units
From March 31, 2022 to June 30, 2022
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
Issuance of common stock under at-the-market sales agreement, net of offering costs of $2,341
1.On April 13, 2022, Aclaris Therapeutics, Inc. (the “Company”) sold 4,838,709 shares of its common stock at a weighted average price per share of $15.50, for aggregate gross proceeds of $75.0 million. The shares were sold pursuant to a sales agreement with SVB Securities LLC and Cantor Fitzgerald & Co. dated May 20, 2021.
From December 31, 2021 to March 31, 2022
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units
From December 31, 2020 to December 31, 2021
Issuance of common stock in connection with exercise of stock options and warrants and vesting of restricted stock units
Issuance of common stock in connection with public offering, net of offering costs of $15,910
From June 30, 2021 to September 30, 2021
Issuance of common stock in connection with vesting of restricted stock units
From March 31, 2021 to June 30, 2021
Issuance of common stock in connection with exercise of stock options and warrants and vesting of restricted stock units
Issuance of common stock in connection with public offering, net of offering costs of $8,899
1.Common Stock offered by Aclaris 7,042,254 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 52,081,729 shares of common stock outstanding as of March 31, 2021.
From December 31, 2020 to March 31, 2021
Issuance of common stock in connection with exercise of stock options and warrants and vesting of restricted stock units
Issuance of common stock in connection with public offering, net of offering costs of $7,011
1.Common Stock offered by Aclaris 5,483,714 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 42,916,387 shares of common stock outstanding as of September 30, 2020.
From December 31,2019 to December 31,2020
Vesting of restricted stock units
Issuance of common stock in connection with an equity purchase agreement, net of offering costs of $168,000
From June 30, 2020 to September 30, 2020
Vesting of restricted stock units
Issuance of common stock in connection with equity purchase agreement
From March 31, 2020 to June 30, 2020
Vesting of restricted stock units
From December 31, 2019 to March 31, 2020
Vesting of RSUs
From December 31, 2018 to December 31, 2019
Exercise of stock options and vesting of RSUs
from June 30, 2019 to September 30, 2019
Exercise of stock options and vesting of RSUs
from March 31, 2019 to June 30, 2019
Exercise of stock options and vesting of RSUs
from December 31, 2018 to March 31, 2019
Vesting of RSUs
from December 31, 2017 to December 31, 2018
Issuance of common stock in connection with public offering, net of offering costs of $6,669
Issuance of common stock in connection with the Confluence development milestone
Exercise of stock options and vesting of RSUs
From December 31, 2017 to September 30, 2018
Exercise of stock options and vesting of RSUs
from December 31, 2017 to June 30, 2018
Exercise of stock options and vesting of RSUs
from December 31, 2017 to March 31, 2018
Exercise of stock options and vesting of RSUs
from December 31, 2016 to December 31, 2017
Issuance of common stock under the at-the-market sales agreement, net of offering costs of $691
Issuance of common stock in connection with public offering, net of offering costs of $5,352
Issuance of common stock in connection with the acquisition of Confluence
Exercise of stock options and vesting of RSUs
From December 31, 2016 to September 30, 2017
Issuance of common stock under the at-the-market sales agreement, net of offering costs of $691
Issuance of common stock in connection with public offering, net of underwriting discounts and commissions and offering costs of $5,352
Issuance of common stock in connection with the acquisition of Confluence
Exercise of stock options and vesting of restricted stock units
From December 31, 2016 to June 30, 2017
Issuance of common stock under the at-the-market sales agreement, net of offering costs of $691
Exercise of stock options and vesting of restricted stock units
from December 31, 2016 to March 31, 2017
Exercise of stock options and vesting of restricted stock units
From December 31, 2015 to December 31, 2016
Issuance of common stock in connection with Vixen acquisition
Issuance of common stock in connection with private placement, net of offering costs of $1,453
Issuance of common stock in connection with follow-on public offering, net of offering costs of $6,492
Exercise of stock options and vesting of RSUs
From December 31, 2015 to September 30, 2016
Issuance of common stock in connection with Vixen acquisition
Issuance of common stock in connection with private placement, net of offering costs of $1,453
Exercise of stock options
from December 31, 2015 to June 30, 2016
Issuance of common stock in connection with Vixen acquisition
Issuance of common stock in connection with private placement, net of offering costs of $1,453,000
Exercise of stock options
from December 31, 2015 to March 31, 2016
Issuance of common stock in connection with Vixen acquisition
from December 31, 2014 to December 31, 2015
Issuance of Series C convertible preferred stock, net of issuance costs of $136
Issuance of common stock in connection with IPO, net of offering costs of $2,272
Issuance of common stock upon conversion of convertible preferred stock
On September 24, 2015, the Company effected a 1-for-3.45 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company’s then-outstanding convertible preferred stock.
a 1-for-3.45 reverse stock split of our common stock effected on September 24, 2015
from January 1, 2015 to September 30, 2015
Issuance of Series C convertible preferred stock, net of issuance costs of $136
On September 24, 2015, the Company effected a one-for-3.45 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company's convertible preferred stock
On September 24, 2015, the Company effected a one-for-3.45 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company's convertible preferred stock
from December 31, 2014 to June 30, 2015
Accretion of redeemable convertible preferred stock to redemption value